NEW YORK (GenomeWeb News) – Novartis, Takeda, The Wellcome Trust, and Daiichi Sankyo have all joined an organized effort to develop and identify genetic markers that could be used to predict which patients may be at risk for experiencing dangerous adverse reactions to specific drugs.
The International Serious Adverse Events Consortium (SAEC), a non-profit group that initially launched a year ago, is a partnership between drug companies, the US Food and Drug Administration, and research institutes.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.